Discriminative Stimulus Effects of Hallucinogenic Drugs: a Possible Relation to Reinforcing and Aversive Effects
Tomohisa Mori, Kazumi Yoshizawa, Masahiro Shibasaki, Tsutomu Suzuki
Journal of Pharmacological Sciences June 12, 2019 DOI: 10.1254/jphs.12r08cp (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Animals |
| Citations | 13 |
| Key findings | Recent research has demonstrated at least two plausible mechanisms for the discriminative stimulus effects of hallucinogenic drugs: one mediated mainly by 5-HT2 receptors, and the other mediated through sigma-1 (σ1)-receptor chaperone regulated by an endogenous hallucinogenic ligand. |
Abstract
The subjective effects of drugs are related to the kinds of feelings they produce, such as euphoria or dysphoria. One of the methods that can be used to study these effects is the drug discrimination procedure. Many researchers are trying to elucidate the mechanisms that underlie the discriminative stimulus effects of abused drugs (e.g., alcohol, psychostimulants, and opioids). Over the past two decades, the patterns of drug abuse have changed, so that club/recreational drugs such as phencyclidine (PCP), 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and ketamine, which induce perceptual distortions, like hallucinations, are now more commonly abused, especially in younger generations. However, the mechanisms of the discriminative stimulus effects of hallucinogenic drugs are not yet fully clear. This review will briefly focus on the recent findings regarding hallucinogenic/psychotomimetic drug–induced discriminative stimulus effects in animals. In summary, recent research has demonstrated that there are at least two plausible mechanisms that can explain the cue of the discriminative stimulus effects of hallucinogenic drugs; one is mediated mainly by 5-HT2 receptors, and the other is mediated through sigma-1 (σ1)-receptor chaperone regulated by endogenous hallucinogenic ligand. Keywords:: discriminative stimulus effect, hallucinogen, serotonin, sigma-1 (σ1) receptor
Citations in the library
Cited by 5
- Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression American Journal of Psychiatry October 1, 2015
- A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids. Frontiers in Psychiatry 2024
- The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behavioural Pharmacology April 1, 2016
- Differential substitution for the discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and methylphenidate in rats. Journal of Pharmacology and Experimental Therapeutics August 2014
- Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice. PLoS One 2014
Cites 13
- When the Endogenous Hallucinogenic Trace AmineN,N-Dimethyltryptamine Meets the Sigma-1 Receptor Science Signaling March 10, 2009
- Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology April 1, 2009
- Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour The International Journal of Neuropsychopharmacology October 14, 2010
- Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers Journal of Psychopharmacology September 3, 2010
- Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade. Naunyn-Schmiedeberg's Archives of Pharmacology February 2011
and 8 more in the library